Drug Profile
MB CART20.1
Alternative Names: Anti-CD20 CAR T cells - Miltenyi Biotec; CD20-targeting CAR T Cells - Miltenyi Biotec; MB-CART20.1Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Miltenyi Biotec GmbH
- Developer German Aerospace Center; Miltenyi Biotec GmbH
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
- No development reported Malignant melanoma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (IV, Infusion)
- 23 Feb 2022 Phase I/II trial is still ongoing for Non-Hodgkin's lymphoma (Second-line therapy or greater) in Germany (NCT03664635)
- 08 Mar 2019 Phase-I clinical trials in Malignant melanoma (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in Germany (IV) (NCT03893019)